| Name | Title | Contact Details |
|---|
JeNu Biosciences was founded by a leading Washington bio scientist and a medical technology entrepreneur. While working on an ultrasound device for topical drug delivery, they became curious about using ultrasound to improve cosmetic skin care product delivery. High energy ultrasound has been proven effective at pushing drugs through the skin, but in the process cells are damaged and high heat causes intense pain. But since cosmetics only need to be absorbed into the top layer of skin rather than through the skin like drugs they thought a low energy ultrasound device might work. After many attempts they proved that low energy ultrasound wouldn`t help on its own. At the same moment, they had the idea that lead to the JeNu System. Rather than using ultrasound energy to vibrate cells in the skin to open up pathways, what if they vibrated microspheres on the skin to open the pathways. This idea lead to patent application 20120271222 and JeNu Biosciences. Launched in 2009, JeNu spent close to $10MM and 5 years on research, development and engineering. JeNu Biosciences is now proud to present the JeNu System. It`s the first pain free, at home, quick way to increase absorption of your favorite skin care products. In just one minute per target area per day the JeNu system is clinically proven to increase absorption by up to 12 times, and improve the efficacy of skin care products by up to 40% in just 7 days.
Quality Health is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
MedicineNet is a San Clemente, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Global Health Strategies (GHS) is an international consulting company that specializes in global health communications, advocacy, research and strategy. We focus on public health issues that impact developing nations and emerging markets. Our clients include leading foundations, industry, NGOs, government agencies, academic institutions and product development. Our work is driven by a passion for improving the health and wellbeing of individuals and communities around the world. We offer the skills, knowledge and goal-driven efficiency to enhance our clients` efforts to address some of the world’s toughest health challenges, including HIV/AIDS, tuberculosis, malaria, polio eradication, sexual and reproductive health and vaccines. GHS has offices in New York, New Delhi, Rio de Janeiro and Beijing, and supports work in countries in Africa, Asia, Europe and the Americas.